Pilot Study to Assess the Safety and Efficacy of Butterfly Medical Prostatic Retraction Device in BPH Patients.

Benign prostatic hyperplasia (BPH) is a non-cancerous enlargement of the prostate gland that may restrict the flow of urine from the bladder. BPH is a cellular proliferative process of the prostate, also referred as enlarged prostate.

An estimated 50% of men demonstrate histopathologic BPH by age 60 years. This number increases to 90% by age 85 years; thus, increasing gland size is considered a normal part of the aging process.

Approximately half of those diagnosed with histopathologic BPH demonstrate moderate-to-severe BPH related symptoms (also known as Lower Urinary Tract Symptoms = LUTS), including urinary frequency, urgency, nocturia (getting up at night during sleep to urinate), decreased or intermittent force of stream, or a sensation of incomplete emptying. Complications occur less commonly but may include acute urinary retention, impaired bladder emptying, or the need for surgery.

In current clinical practice, most patients are initially treated with medical therapy, usually with alpha-blockers. A minimally invasive treatment alternative is the use of urethral stents to preserve flow of urine from the bladder. Such stents are also associated with several problems such as encrustation, stone formation, pain, infection, migration and others. Another alternative is the gold standard treatment for managing benign prostatic hyperplasia; the trans urethral resection of prostate (TURP) surgery. Complications associate with TURP procedure include retrograde ejaculation, urinary incontinence, erectile dysfunction, urethral stricture, and others.

The Butterfly Medical Prostatic Retraction Device is a definitive device intended for transurethral insertion into the male prostatic urethra diagnosed with Bladder Outlet Obstruction (BOO), caused by an enlarged prostate gland. It is a single use device intended to remain permanently in the prostate urethra, to open the occluded urethral passage. The Butterfly device has a specific shape adjusted to fit the prostatic urethral lumen, and is designed to reside only in the prostate urethra without migration to the urinary bladder or the bulbar urethra. Unlike other forms of treatment, the Butterfly device does not inflict any damage to the bladder neck, preventing irritation or retrograde ejaculation.

Inclusion criteria

• Age 50 or older
• Verified BPH with prostate size of at least 30 grams or of 25 mm.
• Signed Informed Consent
• Failure, intolerance or patient non-compliance of medical treatment
• Patients suffering from LUTS symptoms of BPH (IPSS >12, Qmax=<13 ml/sec)
• Patient's voided volume of at least 125 ml in uroflow test
• Patients not eligible for surgery or refusing surgery

Exclusion criteria

• Known sensitivity to Nickel
• Active Prostatitis
• Urethral strictures
• Prior surgery of prostate (simple or radical)
• Currently active bladder tumor
• Suspected neurogenic urinary bladder
• Suspected a-contractile bladder
• Enlarged median lobe of prostate.
• Bladder Neck stricture or contracture
• Urethral pathology: diverticula, strictures, tumors, fistula
• Clinically Significant urinary tract infection
• Uncontrolled bleeding disorders
• Uncontrolled diabetes mellitus
• Severe medical diseases precluding a minimally invasive procedure
• Present active urinary stone disease
• Patients who are under anticoagulants therapy